Search company, investor...

Predict your next investment

Venture Capital
lyzzcap.com

Investments

33

Portfolio Exits

2

Funds

1

About LYZZ Capital

LYZZ Capital is a China-based healthcare, growth, and M&A fund.

Headquarters Location

Room A1103, Tower A, SOHO Fuxing Plaza 388 Ma Dang Road, Huang Pu District

Shanghai, Shanghai,

China

+86 021 61209595

Want to inform investors similar to LYZZ Capital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest LYZZ Capital News

China’s Mojia Biotech Closes Temasek-Led USD80 Million Fundraiser

Jun 24, 2022

(Yicai Global) June 24 -- Mojia Biotech, a Chinese bio-manufacturing company, has raised USD80 million in its latest financing round led by Singaporean sovereign wealth fund Temasek Holdings. Private equity investor Lyzz Capital, which focuses on the biotech sector, and existing shareholders Bits x Bites and Asia Green Fund were among others joining the Series B fundraiser, the Shanghai-based company said in a statement yesterday. The proceeds will be used to speed up commercialization of its Viridimin brand of animal-feed additives, scale up the manufacturing capacity of the Aliphane series of bio-based materials, advance the firm’s product pipeline, and expand its global research and development capabilities, Mojia Biotech added. “Sustainable ingredient manufacturing is a pillar for a thriving green economy,” said Joseph Zhou, managing partner of Bits x Bites. “And with the recent delays and shortages in the global supply chain highlighting the importance of reducing reliance on raw material imports, we see huge potential for Mojia Biotech to apply its technology across different chemical ingredients, and to become a leader for the next-generation green chemical production.” The Viridimin series of vitamin B5 products is expected to go into mass production this month. Compared with traditional production processes, those for Viridimin products use biological manufacturing technologies to save energy and cut emissions, Mojia Biotech pointed out. The Aliphane series of biopolymer products, the firm’s second to be commercialized, is highly versatile and has great potential in coating and adhesive applications, the company said. Editor: Futura Costaglione

LYZZ Capital Investments

33 Investments

LYZZ Capital has made 33 investments. Their latest investment was in Minovia Pharmaceutical as part of their Series A on July 7, 2022.

CBI Logo

LYZZ Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/21/2022

Series A

Minovia Pharmaceutical

Yes

1

7/7/2022

Seed VC

Yiteng Medical

Yes

1

6/23/2022

Series B

Mojia Bio

$80M

Yes

2

4/29/2022

Series A

Subscribe to see more

Subscribe to see more

10

4/22/2022

Series A

Subscribe to see more

Subscribe to see more

10

Date

7/21/2022

7/7/2022

6/23/2022

4/29/2022

4/22/2022

Round

Series A

Seed VC

Series B

Series A

Series A

Company

Minovia Pharmaceutical

Yiteng Medical

Mojia Bio

Subscribe to see more

Subscribe to see more

Amount

$80M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

2

10

10

LYZZ Capital Portfolio Exits

2 Portfolio Exits

LYZZ Capital has 2 portfolio exits. Their latest portfolio exit was Microtech Medical on October 19, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/19/2021

IPO

$99M

Public

5

6/30/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/19/2021

6/30/2021

Exit

IPO

Acquired

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Public

Subscribe to see more

Sources

5

10

LYZZ Capital Fund History

1 Fund History

LYZZ Capital has 1 fund, including Jiangsu Jiequan Lyzz Healthcare Venture Capital Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Jiangsu Jiequan Lyzz Healthcare Venture Capital Fund

Multi-Stage Venture Capital

Open

1

Closing Date

Fund

Jiangsu Jiequan Lyzz Healthcare Venture Capital Fund

Fund Type

Multi-Stage Venture Capital

Status

Open

Amount

Sources

1

LYZZ Capital Team

1 Team Member

LYZZ Capital has 1 team member, including current Managing Partner, Kevin Li.

Name

Work History

Title

Status

Kevin Li

Toucan Capital

Managing Partner

Current

Name

Kevin Li

Work History

Toucan Capital

Title

Managing Partner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.